Journal article
ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer
F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, A Sartore-Bianchi, JF Hechtman, J Christiansen, L Novara, N Tebbutt, G Fucà, C Antoniotti, ST Kim, D Murphy, R Berenato, F Morano, J Sun, B Min, PJ Stephens, M Chen Show all
Journal of the National Cancer Institute | OXFORD UNIV PRESS INC | Published : 2017
DOI: 10.1093/jnci/djx089
Abstract
Background: ALK, ROS1, and NTRK fusions occur in 0.2% to 2.4% of colorectal cancers. Pioneer cases of metastatic colorectal cancer (mCRC) patients bearing rearrangements who benefited from anti-ALK, ROS, and TrkA-B-C therapies have been reported previously. Here we aimed at characterizing the clinical andmolecular landscape of ALK, ROS1, and NTRK rearrangedmCRC. Methods: Clinical features and molecular characteristics of 27 mCRC patients bearing ALK, ROS1, and NTRK rearranged tumors were compared with those of a cohort of 319 patients not bearing rearrangements by means of Fisher's exact, v2 test, or Mann-Whitney test as appropriate. Overall survival curves were estimated with the Kaplan-Mei..
View full abstractGrants
Awarded by Horizon 2020 Framework Programme
Funding Acknowledgements
This work was supported by Fondazione Associazione Ricerche e Cure in Oncologia (ARCO), Italy, and partly supported by grants AIRC IG No. 17707 (FDN); AIRC IG No. 16788 (AB); Fondo per la Ricerca Locale (ex 60%), Universita di Torino, 2014 (FDN); and Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille 2011 Ministero della Salute (AB). Investigators at Niguarda Cancer Center are supported by the following grants: Terapia Molecolare dei Tumori (ASB, SS) and Dynamic of Tumor Evolution and Therapy (ASB) from Fondazione Oncologia Niguarda Onlus; Associazione Italiana per la Ricerca sul Cancro (AIRC) 2010 Special Program Molecular Clinical Oncology 5x1000, project 9970 (SS, AB); European Community's grant agreement No. 635342-2 MoTriColor (AB, SS).